KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding KALA BIO, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 27 | 33 | +6 |
| Shares | 2.12M | 3.46M | +1.34M (+63.4%) |
| Value | $12.1M | $24.0M | +$11.9M (+99.0%) |
New holders (8)
Institutions that held KALA BIO, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cormorant Asset Management, LP | 603,027 | $4.19M | 0.23% |
| Silverarc Capital Management, LLC | 231,070 | $1.60M | 0.36% |
| AIGH Capital Management LLC | 121,302 | $841.8K | 0.32% |
| MAI Capital Management | 300 | $2.08K | 0.00% |
| BNP Paribas Arbitrage, SA | 98 | $680 | 0.00% |
| Curio Wealth, LLC | 20 | $139 | 0.00% |
| SBI Securities Co., Ltd. | 8 | $56 | 0.00% |
| Royal Bank of Canada | 2 | $0 | 0.00% |
Sold out (2)
Institutions that held KALA BIO, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Renaissance Technologies LLC | 21,473 | $122.4K |
| The PNC Financial Services Group, Inc. | 20 | $114 |